Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma ...

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer ...

Faith, from my perspective, is believing in the unseen, and was something I rediscovered following my colon cancer diagnosis.

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.